IgAN

11 registered clinical trials studyying IgAN — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	FXS6837 for the Treatment of IgAN Patients NCT07502638	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Phase 2
Not Yet Recruiting	Efficacy and Safety Study of HS-10542 for IgA Nephropathy NCT07474636	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 2
Recruiting	Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease NCT06989359	ADARx Pharmaceuticals, Inc.	Phase 2
Recruiting	Atacicept in Multiple Glomerular Diseases NCT06983028	Vera Therapeutics, Inc.	Phase 2
Recruiting	Study of Ravulizumab in Pediatric Participants With Primary IgAN NCT07024563	Alexion Pharmaceuticals, Inc.	Phase 3
Recruiting	Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) NCT06291376	Alexion Pharmaceuticals, Inc.	Phase 3
Terminated	Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) NCT05125068	Eledon Pharmaceuticals	Phase 2
Terminated	Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) NCT05097989	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	Safety and Efficacy Study of VIS649 for IgA Nephropathy NCT04287985	Visterra, Inc.	Phase 2
Terminated	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 NCT02682407	Omeros Corporation	Phase 2
Terminated	Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus NCT02523768	Centre Hospitalier Universitaire de Saint Etienne	Phase 4